What You Need To Know
On the morning of Wednesday, September 4, 2024, Hackensack University Medical Center became the first hospital in the world to treat patients with Aquablation® therapy using the new HYDROS™ Robotic System. This next-generation platform treats men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.
Aquablation therapy is an innovative approach - delivering a heat-free waterjet so intense - that removes excess prostate tissue. The new HYDROS System is now delivered by an AI-powered robot that is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes – a combination of benefits previously unattainable with traditional treatments.
BPH is a common consequence of aging, affecting half of all men between the ages of 51 and 60, with as many as 99% reporting a decrease in their quality of life. BPH impairs urinary function, making it considerably more difficult to urinate. Common symptoms include a weak urinary stream, a frequent or urgent need to urinate, nighttime urination, and trouble fully emptying the bladder. If left untreated, BPH can lead to serious health problems such as urinary tract infections, bladder stones, incontinence, retention of urine, and permanent bladder or kidney damage. When medications prove ineffective or cause troublesome side effects, surgery is often the standard treatment option; however, many surgical procedures can negatively affect sexual function and continence.
Aquablation therapy was designed to offer a minimally invasive and effective solution for BPH, minimizing the need for men to choose between safety and efficacy. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets which prostate tissue to remove and which to preserve. With this tailored approach, the system accurately removes problematic tissue while safeguarding critical anatomy.
The HYDROS Robotic System represents the next evolution in Aquablation therapy. It features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. It integrates next-generation ultrasound imaging and digital cystoscopy, providing surgeons with a multi-dimensional, detailed view of the entire prostate. The HYDROS System is designed to improve efficiency, enhance surgeon and staff experience, and deliver more accurate and consistent treatment plans for better clinical outcomes.
For more information on Aquablation therapy, visit aquablation.com.